Literature DB >> 10598622

First-pass lung uptake and pulmonary clearance of propofol: assessment with a recirculatory indocyanine green pharmacokinetic model.

J A Kuipers1, F Boer, W Olieman, A G Burm, J G Bovill.   

Abstract

BACKGROUND: The principal site for elimination of propofol is the liver. The clearance of propofol exceeds hepatic blood flow; therefore, extrahepatic clearance is thought to contribute to its elimination. This study examined the pulmonary kinetics of propofol using part of an indocyanine green (ICG) recirculatory model.
METHODS: Ten sheep, immobilized in a hammock, received injections of propofol (4 mg/kg) and ICG (25 mg) via two semipermanent catheters in the right internal jugular vein. Arterial blood samples were obtained from the carotid artery. The ICG injection was given for measurement of intravascular recirculatory parameters and determination of differences in propofol and ICG concentration-time profiles. No other medication was given during the experiment, and the sheep were not intubated. The arterial concentration-time curves of ICG were analyzed with a recirculatory model. The pulmonary uptake and elimination of propofol was analyzed with the central part of that model extended with a pulmonary tissue compartment allowing elimination from that compartment.
RESULTS: During the experiment, cardiac output was 3.90+/-0.72 l/min (mean +/- SD). The blood volume in heart and lungs, measured with ICG, was 0.66+/-0.07 l. A pulmonary tissue compartment of 0.47+/-0.16 l was found for propofol. The pulmonary first-pass elimination of propofol was 1.14+/-0.23 l/min. Thirty percent of the dose was eliminated during the first pass through the lungs.
CONCLUSIONS: Recirculatory modeling of ICG allows modeling of the first-pass pulmonary kinetics of propofol concurrently. Propofol undergoes extensive uptake and first-pass elimination in the lungs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598622     DOI: 10.1097/00000542-199912000-00032

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

1.  Pharmacokinetics of propofol in calves undergoing abdominal surgery.

Authors:  P Cagnardi; A Zonca; M Gallo; D Pravettoni; N Morandi; R Villa; S Carli
Journal:  Vet Res Commun       Date:  2009-09       Impact factor: 2.459

2.  Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain.

Authors:  Haruhiko Hiraoka; Koujirou Yamamoto; Soutarou Miyoshi; Toshihiro Morita; Katsunori Nakamura; Yuuji Kadoi; Fumio Kunimoto; Ryuya Horiuchi
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

3.  Propofol preferentially relaxes neurokinin receptor-2-induced airway smooth muscle contraction in guinea pig trachea.

Authors:  Neil R Gleason; George Gallos; Yi Zhang; Charles W Emala
Journal:  Anesthesiology       Date:  2010-06       Impact factor: 7.892

4.  Endogenous gamma-aminobutyric acid modulates tonic guinea pig airway tone and propofol-induced airway smooth muscle relaxation.

Authors:  George Gallos; Neil R Gleason; Laszlo Virag; Yi Zhang; Kentaro Mizuta; Robert A Whittington; Charles W Emala
Journal:  Anesthesiology       Date:  2009-04       Impact factor: 7.892

5.  Required propofol dose for anesthesia and time to emerge are affected by the use of antiepileptics: prospective cohort study.

Authors:  Kentaro Ouchi; Kazuna Sugiyama
Journal:  BMC Anesthesiol       Date:  2015-03-15       Impact factor: 2.217

6.  Hypercapnic hyperventilation shortens emergence time from Propofol and Isoflurane anesthesia.

Authors:  Ahmad Yaraghi; Mohammad Golparvar; Reihanak Talakoub; Hossein Sateie; Ali Mehrabi
Journal:  J Res Pharm Pract       Date:  2013-01

7.  Hypercapnia does not shorten emergence time from propofol anesthesia: a pilot randomized clinical study.

Authors:  Ki-Hyug Kwon; Hansu Bae; Hyun Gu Kang; Junyong In
Journal:  Korean J Anesthesiol       Date:  2018-04-25

Review 8.  Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Biomed Res Int       Date:  2018-05-24       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.